Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Public ClinicalTrials.gov record NCT02544633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification \[increase number of gene copies\]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.
Study identification
- NCT ID
- NCT02544633
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2015 (Type not available)
- Primary completion
- Apr 30, 2018 (Actual)
- Completion
- Jan 2019 (Actual)
- Last update posted
- Mar 4, 2020
2015 – 2019
United States locations
- U.S. sites
- 47
- U.S. states
- 25
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| Fowler Family Center for Cancer Care | Jonesboro | Arkansas | 72401 | — |
| Providence Saint Joseph Medical Center | Burbank | California | 91505 | — |
| Saint Joseph Heritage Healthcare | Fullerton | California | 92835-3825 | — |
| University of California San Diego | La Jolla | California | 92121 | — |
| Loma Linda University Medical Center | Loma Linda | California | 92354 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Innovative Clinical Reseach Institute | Whittier | California | 90603 | — |
| St. Mary's Regional Cancer Center | Grand Junction | Colorado | 81501 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Boca Raton Regional Hospital - Eugene M. & Christine E. Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Sylvester Comprehensive Cancer Center | Deerfield Beach | Florida | 33442-7753 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Mercy Cancer Center | Mason City | Iowa | 50401 | — |
| Oncology-Hematology Associates, PA | Danville | Kentucky | 40422-2534 | — |
| Lexington Oncology Associates, LLC | Lexington | Kentucky | 40503 | — |
| Kentuckyone Health Cancer and Blood Speacialists | Louisville | Kentucky | 40245 | — |
| Christus Saint Frances Cabrini Hospital | Alexandria | Louisiana | 71301 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| The University of New Mexico Cancer Research and Treatment Center | Albuquerque | New Mexico | 87102 | — |
| Queens Cancer Center | Jamaica | New York | 11430 | — |
| Clinical Research Alliance | New York | New York | 10021 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Guthrie Cancer Center | Sayre | Pennsylvania | 18840 | — |
| Greenville Health System | Greenville | South Carolina | 29615 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 752010 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02544633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2020 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02544633 live on ClinicalTrials.gov.